.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,858,203

« Back to Dashboard

Claims for Patent: 6,858,203

Title: Method of making phosphate-binding polymers for oral administration
Abstract:Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
Inventor(s): Holmes-Farley; Stephen Randall (Arlington, MA), Mandeville, III; W. Harry (Lynnfield, MA), Whitesides; George M. (Newton, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:10/322,904
Patent Claims: 1. A method for removing phosphate from a patient comprising orally administering to said patient a therapeutically effective amount of a composition comprising at least one polymer characterized by a repeat unit having the formula: ##STR28##

or a copolymer thereof, wherein each n is an integer, each R, independently, is H or a lower alkyl, alkylamino, or aryl group, and each X.sup.- is a carbonate or bicarbonate anion.

2. The method of claim 1 wherein said polymer is crosslinked with a crosslinking agent wherein said crosslinking agent is present in said composition from about 0.5% to about 75% by weight.

3. The method of claim 2 wherein said crosslinking agent comprises epichlorohydrin, 1,4 butanedioldiglycidyl ether, 1,2 ethanedioldiglycidyl ether, 1,3-dichloropropane, 1,2-dichloroethane, 1,3-dibromopropane, 1,2-dibromoethane, succinyl dichloride, dimethylsuccinate, toluene diisocyanate, acryloyl chloride, or pyromellitic dianhydride.

4. The method of claim 2 wherein said crosslinking agent is present in said composition from about 2% to about 20% by weight.

5. The method of claim 1 wherein the polymer is a copolymer comprising a second repeat unit having the formula: ##STR29##

wherein each n, independently, is an integer and each R, independently, is H or a lower alkyl, alkylamino, or aryl group.

6. The method of claim 5 wherein said copolymer is crosslinked with a crosslinking agent wherein said crosslinking agent is present in said composition from about 0.5% to about 75% by weight.

7. The method of claim 6 wherein said crosslinking agent comprises epichlorohydrin, 1,4 butanedioldiglycidyl ether, 1,2 ethanedioldiglycidyl ether, 1,3-dichloropropane, 1,2-dichloroethane, 1,3-dibromopropane, 1,2-dibromoethane, succinyl dichloride, dimethylsuccinate, toluene diisocyanate, acryloyl chloride, or pyromellitic dianhydride.

8. The method of claim 6 wherein said crosslinking agent is present in said composition from about 2% to about 20% by weight.

9. A method for removing phosphate from a patient comprising orally administering to said patient a therapeutically effective amount of a composition comprising a copolymer characterized by a repeat unit having the formula: ##STR30##

and a second repeat unit having the formula: ##STR31##

wherein said copolymer is crosslinked with epichlorohydrin, wherein epichlorohydrin is present in said composition from about 2% to about 20% by weight and wherein each n is an integer, each R is H, and each X.sup.- 0 is a carbonate or bicarbonate anion.

10. A pharmaceutical composition comprising a carrier and a therapeutically effective amount of at least one polymer characterized by a repeat unit having the formula: ##STR32##

or a copolymer thereof, wherein each n is an integer, each R, independently, is H or a lower alkyl, alkylamino, or aryl group, and each X.sup.- is a carbonate or bicarbonate anion.

11. The pharmaceutical composition of claim 10 wherein said polymer is crosslinked with a crosslinking agent wherein said crosslinking agent is present in said composition from about 0.5% to about 75% by weight.

12. The pharmaceutical composition of claim 11 wherein said crosslinking agent comprises epichlorohydrin, 1,4 butanedioldiglycidyl ether, 1,2 ethanedioldiglycidyl ether, 1,3-dichloropropane, 1,2-dichloroethane, 1,3-dibromopropane, 1,2-dibromoethane, succinyl dichloride, dimethylsuccinate, toluene diisocyanate, acryloyl chloride, or pyromellitic dianhydride.

13. The pharmaceutical composition of claim 11 wherein said crosslinking agent is present in said composition from about 2% to about 20% by weight.

14. The pharmaceutical composition of claim 10 wherein the polymer is a copolymer comprising a second repeat unit having the formula: ##STR33##

wherein each n, independently, is an integer and each R, independently, is H or a lower alkyl, alkylamino, or aryl group.

15. The pharmaceutical composition of claim 14 wherein said copolymer is crosslinked with a crosslinking agent wherein said crosslinking agent is present in said composition from about 0.5% to about 75% by weight.

16. The pharmaceutical composition of claim 15 wherein said crosslinking agent comprises epichlorohydrin, 1,4 butanedioldiglycidyl ether, 1,2 ethanedioldiglycidyl ether, 1,3-dichloropropane, 1,2-dichloroethane, 1,3dibromopropane, 1,2-dibromoethane, succinyl dichloride, dimethylsuccinate, toluene diisocyanate, acryloyl chloride, or pyromellitic dianhydride.

17. The pharmaceutical composition of claim 15 wherein said crosslinking agent is present in said composition from about 2% to about 20% by weight.

18. A pharmaceutical composition comprising a carrier and a therapeutically effective amount of a copolymer characterized by a repeat unit having the formula: ##STR34##

and a second repeat unit having the formula: ##STR35##

wherein said copolymer is crosslinked with epichlorohydrin, wherein epichlorohydrin is present in said composition from about 2% to about 20% by weight and wherein each n is an integer, each R is H, and each X.sup.- is a carbonate or bicarbonate anion.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc